May 24, 2017 7:02 AM ET


Company Overview of Sun BioPharma, Inc.

Company Overview

Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing disruptive therapeutics for severe unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase I clinical trial for the treatment of patients with pancreatic cancer. The company has scientific collaborations with pancreatic disease experts Cedars Sinai Medical Center in Los Angeles, the University of Miami; the University of Florida; the Mayo Clinic Scottsdale; the Austin Health Cancer Trials Centre in Melbourne, Australia; and the Ashford Cancer Centre in Adelaide, Australia. Sun BioPharma, Inc...

712 Vista Boulevard

Suite 305

Waconia, MN 55387

United States

Founded in 2011

6 Employees



Key Executives for Sun BioPharma, Inc.

Chief Executive Officer, President and Director
Age: 66
Total Annual Compensation: $248.9K
Co-founder and Executive Chairman
Age: 70
Total Annual Compensation: $199.4K
Chief Financial Officer, Vice President of Finance, Secretary and Treasurer
Age: 51
Total Annual Compensation: $209.0K
Compensation as of Fiscal Year 2016.

Sun BioPharma, Inc. Key Developments

Sun BioPharma, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended of December 31, 2016

Sun BioPharma, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended of December 31, 2016. For the quarter, the company reported operating loss of $2,113,000 compared to $1,230,000 a year ago. Loss before income tax benefit was $2,326,000 compared to $1,290,000 a year ago. Net loss was $2,235,000 compared to $595,000 a year ago. Basic and diluted net loss per share was $0.07 compared to $0.02 a year ago. For the full year, the company reported operating loss of $5,168,000 compared to $5,444,000 a year ago. Loss before income tax benefit was $5,453,000 compared to $5,683,000 a year ago. Net loss was $5,112,000 compared to $4,927,000 a year ago. Basic and diluted net loss per share was $0.16 compared to $0.35 a year ago. Net cash used in operating activities was $2,398,000 compared to $3,897,000 a year ago. The net cash used in each of these periods primarily reflects the net loss for these periods, partially offset in part by non-cash charges recorded for share-based compensation and the effects of changes in operating assets and liabilities.

Sun BioPharma Inc. Announces Interim Data from Phase I Pancreatic Cancer Study

Sun BioPharma, Inc. has announced interim data from the Phase I dose-escalation phase of its clinical study for SBP-101 indicated for the treatment of pancreatic cancer. As previously announced on December 7, 2016, the company completed cycle 1 dosing of patients in the fourth cohort and initiated enrollment of the fifth cohort in the dose-escalation phase of the study. The company expects that the additional patients in the fifth cohort will complete cycle 1 dosing early in the second quarter of 2017. Through four completed cohorts, 15 patients have received escalating doses of SBP-101. Seven patients were dosed in the third and fourth cohorts, three of whom have shown stable disease at the eight-week conclusion of their first cycle of treatment, using the independently published Response Evaluation Criteria in Solid Tumors ("RECIST") criteria. These early signs of efficacy were unexpected due to the low doses of SBP-101 administered in these two cohorts and given that six of the seven patients were enrolled in the study after receiving two or more unsuccessful chemotherapy regimens.

Sun BioPharma, Inc. Auditor Raises 'Going Concern' Doubt

Sun BioPharma, Inc. filed its 10-K on Mar 30, 2017 for the period ending Dec 31, 2016. In this report its auditor, Cherry, Bekaert & Holland, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
February 17, 2017
Private Placement
June 10, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sun BioPharma, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at